Greystone Managed Investments Inc. decreased its position in Celgene Corp. (NASDAQ:CELG) by 7.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,818 shares of the biopharmaceutical company’s stock after selling 4,556 shares during the period. Greystone Managed Investments Inc.’s holdings in Celgene Corp. were worth $5,505,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Jolley Asset Management LLC raised its position in Celgene Corp. by 58.8% in the second quarter. Jolley Asset Management LLC now owns 1,215 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 450 shares during the period. Smithfield Trust Co. increased its position in Celgene Corp. by 12.5% in the second quarter. Smithfield Trust Co. now owns 1,282 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 142 shares in the last quarter. Kings Point Capital Management increased its position in Celgene Corp. by 1.7% in the first quarter. Kings Point Capital Management now owns 1,316 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 22 shares in the last quarter. Integrated Investment Consultants LLC increased its position in Celgene Corp. by 21.8% in the second quarter. Integrated Investment Consultants LLC now owns 1,339 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 240 shares in the last quarter. Finally, Ropes Wealth Advisors LLC increased its position in Celgene Corp. by 0.9% in the first quarter. Ropes Wealth Advisors LLC now owns 1,477 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 13 shares in the last quarter. 77.75% of the stock is currently owned by institutional investors and hedge funds.

Celgene Corp. (NASDAQ:CELG) traded up 1.03% during trading on Wednesday, hitting $109.54. 672,975 shares of the company traded hands. Celgene Corp. has a one year low of $93.05 and a one year high of $128.39. The firm has a market cap of $84.91 billion, a P/E ratio of 46.30 and a beta of 1.31. The firm has a 50 day moving average of $110.21 and a 200 day moving average of $105.03.

Celgene Corp. (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.05. The firm had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.70 billion. Celgene Corp. had a net margin of 18.95% and a return on equity of 67.06%. The company’s revenue for the quarter was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.23 EPS. On average, analysts expect that Celgene Corp. will post $5.71 earnings per share for the current fiscal year.

Several research firms have issued reports on CELG. Canaccord Genuity set a $156.00 price objective on shares of Celgene Corp. and gave the company a “buy” rating in a research note on Sunday. Morgan Stanley restated a “hold” rating on shares of Celgene Corp. in a research note on Thursday, June 30th. Cowen and Company restated a “buy” rating and issued a $150.00 price objective on shares of Celgene Corp. in a research note on Thursday, July 28th. Leerink Swann restated a “market perform” rating and issued a $135.00 price objective on shares of Celgene Corp. in a research note on Monday, September 12th. Finally, Jefferies Group restated a “buy” rating and issued a $140.00 price objective on shares of Celgene Corp. in a research note on Wednesday, June 29th. Four research analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Celgene Corp. has an average rating of “Buy” and a consensus target price of $138.10.

In other Celgene Corp. news, insider Robert J. Hugin sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $110.00, for a total value of $11,000,000.00. Following the transaction, the insider now owns 1,022,201 shares in the company, valued at approximately $112,442,110. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director James J. Loughlin sold 27,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $114.10, for a total transaction of $3,137,750.00. Following the completion of the transaction, the director now owns 42,919 shares in the company, valued at approximately $4,897,057.90. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by company insiders.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corp. (NASDAQ:CELG).

Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.